KF
TEVA icon

Krilogy Financial’s Teva Pharmaceuticals TEVA Stock Holding History

Krilogy Financial’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-150
Closed -$3K – 840
2017
Q3 		$3K Buy
+150
New +$3.38K ﹤0.01% 712
2017
Q2 		– Sell
-934
Closed -$34K – 776
2017
Q1 		$34K Hold
934
– – 0.01% 346
2016
Q4 		$34K Sell
934
-11
-1% -$439 0.01% 346
2016
Q3 		$43K Sell
945
-1,690
-64% -$88.2K 0.01% 316
2016
Q2 		$132K Buy
2,635
+25
+1% +$1.33K 0.05% 170
2016
Q1 		$140K Buy
2,610
+1,850
+243% +$109K 0.06% 134
2015
Q4 		$50K Buy
760
+175
+30% +$10.8K 0.05% 134
2015
Q3 		$33K Buy
+585
New +$37.9K 0.02% 258

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Krilogy Financial's TEVA Position: Q4 2017 in Review

Krilogy Financial sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 150 shares — an estimated $3K sold.

Krilogy Financial first reported a position in TEVA in Q3 2015 and held it in 8 quarters. The position peaked at $140K in Q1 2016. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Krilogy Financial reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Krilogy Financial sold 150 Teva Pharmaceuticals shares in Q4 2017, an estimated $3K.
  • Krilogy Financial first reported a position in Teva Pharmaceuticals in Q3 2015 and held it in 8 quarters.
  • Krilogy Financial's Teva Pharmaceuticals position peaked at $140K in Q1 2016.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Krilogy Financial's 13F filing for Q4 2017, filed 14 Feb 2018.